My watch list

Ipratropium/salbutamol

Ipratropium/salbutamol
Combination of
Ipratropium	Muscarinic antagonist
Salbutamol	Short-acting β2-adrenergic agonist
Identifiers
CAS number	?
ATC code	?
PubChem	?
Therapeutic considerations
Pregnancy cat.	?
Legal status
Routes	Inhalation

The combination preparation ipratropium/salbutamol is a formulation containing ipratropium bromide and salbutamol sulfate (albuterol sulfate) used in the management of chronic obstructive pulmonary disease (COPD) and asthma. It is marketed by Boehringer Ingelheim as metered dose inhaler (MDI) and nebuliser preparations under the trade name Combivent.

v • d • e Drugs for obstructive airway diseases: asthma/COPD (R03)
Adrenergics, inhalants	Short acting β₂-agonists: Salbutamol/Levosalbutamol • Fenoterol • Terbutaline Long acting β₂-agonists (LABA): Bambuterol • Clenbuterol • Formoterol • Salmeterol other: Epinephrine • Isoproterenol • Orciprenaline
Glucocorticoids	Beclometasone • Budesonide • Ciclesonide • Fluticasone • Mometasone
Anticholinergics	Ipratropium • Tiotropium
Mast cell stabilizers	Cromoglicate • Nedocromil
Xanthines	Aminophylline • Theobromine • Theophylline
Leukotriene antagonists	Montelukast • Pranlukast • Zafirlukast
Combination products	Budesonide/formoterol • Fluticasone/salmeterol • Ipratropium/salbutamol